RU98100213A - COMPOSITIONS INCLUDING BIOLOGICAL AGENT - Google Patents
COMPOSITIONS INCLUDING BIOLOGICAL AGENTInfo
- Publication number
- RU98100213A RU98100213A RU98100213/14A RU98100213A RU98100213A RU 98100213 A RU98100213 A RU 98100213A RU 98100213/14 A RU98100213/14 A RU 98100213/14A RU 98100213 A RU98100213 A RU 98100213A RU 98100213 A RU98100213 A RU 98100213A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- carbon atoms
- polyester block
- block copolymer
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 86
- 239000003124 biologic agent Substances 0.000 title claims 9
- 229920001400 block copolymer Polymers 0.000 claims 55
- 229920000728 polyester Polymers 0.000 claims 51
- 125000004432 carbon atoms Chemical group C* 0.000 claims 48
- 230000002209 hydrophobic Effects 0.000 claims 44
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 229920000642 polymer Polymers 0.000 claims 29
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 14
- 239000007864 aqueous solution Substances 0.000 claims 14
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- -1 amino, sulfonyl Chemical group 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 8
- 239000000693 micelle Substances 0.000 claims 8
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 6
- 230000001093 anti-cancer Effects 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 239000000969 carrier Substances 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 229920001577 copolymer Polymers 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 230000001154 acute Effects 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 230000001472 cytotoxic Effects 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 3
- 230000036457 multidrug resistance Effects 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 2
- 229960000908 Idarubicin Drugs 0.000 claims 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- 206010027476 Metastasis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004429 atoms Chemical group 0.000 claims 2
- 230000003115 biocidal Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- 238000005755 formation reaction Methods 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatoms Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 230000003000 nontoxic Effects 0.000 claims 2
- 231100000252 nontoxic Toxicity 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-Aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 claims 1
- MELGDFBIPJROHZ-UHFFFAOYSA-N 9-acetyl-7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-9,11-dihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound C1=2C=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 MELGDFBIPJROHZ-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 1
- 229960003071 Bacitracin Drugs 0.000 claims 1
- 108010001478 Bacitracin Proteins 0.000 claims 1
- 229960001561 Bleomycin Drugs 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 229950001725 CARUBICIN Drugs 0.000 claims 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N CARUBICIN Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 claims 1
- 229960005091 Chloramphenicol Drugs 0.000 claims 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N Clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims 1
- 229960000860 Dapsone Drugs 0.000 claims 1
- 229960000975 Daunorubicin Drugs 0.000 claims 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Di(p-aminophenyl)sulphone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- 229960001904 EPIRUBICIN Drugs 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 1
- AEUTYOVWOVBAKS-UWVGGRQHSA-N Ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 claims 1
- 229960000285 Ethambutol Drugs 0.000 claims 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N Ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 Etoposide Drugs 0.000 claims 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N Flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 229940093912 Gynecological Sulfonamides Drugs 0.000 claims 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N Hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims 1
- 206010020243 Hodgkin's disease Diseases 0.000 claims 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 229960004011 Methenamine Drugs 0.000 claims 1
- 229960004857 Mitomycin Drugs 0.000 claims 1
- 229960001156 Mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- JQXXHWHPUNPDRT-ZNQWNCHJSA-N O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)Nc2c(O)c3c(O)c4C)C)OC)c4c1c3c(O)c2C=NN1CCN(C)CC1 Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)Nc2c(O)c3c(O)c4C)C)OC)c4c1c3c(O)c2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-ZNQWNCHJSA-N 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N Pyrazinamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 1
- 229960005206 Pyrazinamide Drugs 0.000 claims 1
- 229940081190 Rifampin Drugs 0.000 claims 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- NEDPPCHNEOMTJV-UHFFFAOYSA-N Sulfoxone Chemical compound C1=CC(NCS(=O)O)=CC=C1S(=O)(=O)C1=CC=C(NCS(O)=O)C=C1 NEDPPCHNEOMTJV-UHFFFAOYSA-N 0.000 claims 1
- 229960002180 Tetracycline Drugs 0.000 claims 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- 229960003165 Vancomycin Drugs 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 241000863480 Vinca Species 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 229950006704 aldesulfone Drugs 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 229930013930 alkaloids Natural products 0.000 claims 1
- 229960004909 aminosalicylic acid Drugs 0.000 claims 1
- 229960003942 amphotericin B Drugs 0.000 claims 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 claims 1
- 230000003432 anti-folate Effects 0.000 claims 1
- 230000000845 anti-microbial Effects 0.000 claims 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims 1
- 239000003781 beta lactamase inhibitor Substances 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960002227 clindamycin Drugs 0.000 claims 1
- 229960004287 clofazimine Drugs 0.000 claims 1
- 229960001338 colchicine Drugs 0.000 claims 1
- 229960003077 cycloserine Drugs 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 229960003276 erythromycin Drugs 0.000 claims 1
- 229960002001 ethionamide Drugs 0.000 claims 1
- 229960004413 flucytosine Drugs 0.000 claims 1
- 239000004052 folic acid antagonist Substances 0.000 claims 1
- 230000002518 glial Effects 0.000 claims 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 claims 1
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 claims 1
- 229960003350 isoniazid Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000006439 lymphocytic leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000000813 microbial Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003449 preventive Effects 0.000 claims 1
- 150000007660 quinolones Chemical class 0.000 claims 1
- 229960001225 rifampicin Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 229940040975 systemic penicillins Beta-lactamase inhibitors Drugs 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 229940026752 topical Sulfonamides Drugs 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 239000002132 β-lactam antibiotic Substances 0.000 claims 1
Claims (73)
А-В-А' (I)
А-В (II)
В-А-В' (III)
L(R1)(R2)(R3)(R4) (IV),
где А и А' обозначают линейные полимерные сегменты типа А, В и В' обозначают линейные полимерные сегменты типа В и R1, R2, R3 и R4 представляют собой (1) блоксополимеры формул (I), (II) или (III) или (2) водород, a L является связующей группой, при условии, что не более, чем два из R1, R2, R3 или R4 являются водородами, и их смесей.5. The composition according to claim 1, characterized in that said block copolymer is selected from the group consisting of polymers of the following formulas
A-B-A '(I)
A-B (II)
B-A-B '(III)
L (R 1 ) (R 2 ) (R 3 ) (R 4 ) (IV),
where A and A ′ denote linear polymer segments of type A, B and B ′ denote linear polymer segments of type B and R 1 , R 2 , R 3 and R 4 are (1) block copolymers of formulas (I), (II) or ( III) or (2) hydrogen, a L is a linking group, provided that no more than two of R 1 , R 2 , R 3 or R 4 are hydrogens, and mixtures thereof.
где n и m обозначают целые числа от примерно 4 до примерно 400.20. The composition according to p. 1, characterized in that the polyester block copolymer has the formula
where n and m are integers from about 4 to about 400.
А-В-А' (I)
А-В (II)
В-А-В' (III) или
L(R1)(R2)(R3)(R4) (IV),
где А и А' обозначают линейные полимерные сегменты типа А, В и В' обозначают линейные полимерные сегменты типа В, и R1, R2, R3 и R4 представляют собой (1) блоксополимеры формул (I), (II) или (III) или (2) водород, a L является связующей группой, при условии, что не более, чем два из R1, R2, R3 или R4 являются водородами, и их смесей.36. The composition according to p, characterized in that the block copolymer selected from the group consisting of polymers of the following formulas
A-B-A '(I)
A-B (II)
B-A-B '(III) or
L (R 1 ) (R 2 ) (R 3 ) (R 4 ) (IV),
where A and A ′ are linear polymer segments of type A, B and B ′ are linear polymer segments of type B, and R 1 , R 2 , R 3 and R 4 are (1) block copolymers of formulas (I), (II) or (III) or (2) hydrogen, a L is a linking group, provided that no more than two of R 1 , R 2 , R 3 or R 4 are hydrogens, and mixtures thereof.
где n и m обозначают целые числа от примерно 4 до примерно 400.48. The composition according to clause 35, wherein the specified polyester block copolymer has the formula
where n and m are integers from about 4 to about 400.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/478,978 | 1995-06-07 | ||
US08/478,978 US5817321A (en) | 1992-10-08 | 1995-06-07 | Biological agent compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
RU98100213A true RU98100213A (en) | 1999-11-27 |
RU2166934C2 RU2166934C2 (en) | 2001-05-20 |
Family
ID=23902177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU98100213/14A RU2166934C2 (en) | 1995-06-07 | 1996-06-07 | Compositions containing biological agent |
Country Status (12)
Country | Link |
---|---|
US (1) | US5817321A (en) |
EP (2) | EP0871432B1 (en) |
JP (1) | JP4167299B2 (en) |
CN (1) | CN1192678A (en) |
AT (1) | ATE253352T1 (en) |
AU (1) | AU700021B2 (en) |
BR (1) | BR9609176A (en) |
CA (1) | CA2222776A1 (en) |
DE (1) | DE69630615T2 (en) |
NZ (1) | NZ313271A (en) |
RU (1) | RU2166934C2 (en) |
WO (1) | WO1996040055A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD4009C2 (en) * | 2008-07-15 | 2010-08-31 | Институт Химии Академии Наук Молдовы | Use of 1-methyl-4-(N-methylaminobutyl-4)-b-carboline as antituberculous remedy |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6093391A (en) * | 1992-10-08 | 2000-07-25 | Supratek Pharma, Inc. | Peptide copolymer compositions |
US6221959B1 (en) | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
US6353055B1 (en) | 1994-11-18 | 2002-03-05 | Supratek Pharma Inc. | Polynucleotide compositions |
US6040295A (en) | 1995-01-13 | 2000-03-21 | Genemedicine, Inc. | Formulated nucleic acid compositions and methods of administering the same for gene therapy |
EP0832653A1 (en) * | 1996-09-20 | 1998-04-01 | Max-Delbrück-Centrum Für Molekulare Medizin | Use of cytokines and cytotoxic compounds in a method for treatment of tumours |
US20020115609A1 (en) * | 1997-07-14 | 2002-08-22 | Hayat Onyuksel | Materials and methods for making improved micelle compositions |
US20050025819A1 (en) * | 1997-07-14 | 2005-02-03 | Hayat Onyuksel | Materials and methods for making improved micelle compositions |
US5948896A (en) * | 1997-08-13 | 1999-09-07 | Gem Pharmaceuticals | Processes for preparing 13-deoxy anthracycline derivatives |
WO2000069942A1 (en) * | 1999-05-19 | 2000-11-23 | University Of Utah Research Foundation | Stabilization and acoustic activation of polymeric micelles for drug delivery |
US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
ATE304870T1 (en) * | 1999-10-29 | 2005-10-15 | Los Angeles Childrens Hospital | METHOD AND MATERIAL FOR HEMOSTASIS IN BONE |
US9616150B2 (en) * | 1999-10-29 | 2017-04-11 | Children's Hospital Los Angeles | Bone hemostasis method and materials |
IL141438A0 (en) * | 2000-02-23 | 2002-03-10 | Pfizer Prod Inc | Method of increasing the bioavailability and tissue penetration of azithromycin |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US7256180B2 (en) | 2000-04-28 | 2007-08-14 | Supratek Pharma Inc. | Compositions and methods for inducing activation of dendritic cells |
TWI249519B (en) | 2000-08-29 | 2006-02-21 | Nobex Corp | Immunoregulatory compounds and derivatives and methods of treating diseases therewith |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
SE0101702D0 (en) | 2001-05-15 | 2001-05-15 | Ardenia Investments Ltd | Novel potentiating compounds |
GB0120701D0 (en) * | 2001-08-24 | 2001-10-17 | Maelor Pharmaceuticals Ltd | Pharmaceutical formulations |
US8048924B2 (en) | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
RU2004119557A (en) * | 2001-12-20 | 2005-04-20 | Бристол-Маерс Сквибб Компани (Us) | PHARMACEUTICAL COMPOSITIONS OF ORAL-ACTIVE DERIVATIVES OF TAXANA WITH INCREASED BIOAVAILABILITY |
AU2003212888A1 (en) * | 2002-02-06 | 2003-09-02 | Combinatorx, Incorporated | Combinations for the treatment of fungal infections |
AR039744A1 (en) * | 2002-06-26 | 2005-03-09 | Alza Corp | METHODS AND DOSAGE FORMS TO INCREASE THE SOLUBILITY OF PHARMACOS COMPOSITIONS FOR CONTROLLED ADMINISTRATION |
US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
WO2004010970A1 (en) * | 2002-07-29 | 2004-02-05 | Alza Corporation | Formulations and dosage forms for controlled delivery of topiramate |
TWI367113B (en) | 2003-02-12 | 2012-07-01 | Syncera Inc | Random and non-random alkylene oxide polymer alloy compositions |
CA2533178C (en) | 2003-07-21 | 2014-03-11 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
CA2533292C (en) | 2003-07-21 | 2013-12-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
WO2005009364A2 (en) | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
WO2005016306A2 (en) * | 2003-08-06 | 2005-02-24 | Alza Corporation | Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation |
WO2005016311A1 (en) | 2003-08-11 | 2005-02-24 | Advancis Pharmaceutical Corporation | Robust pellet |
AU2004264356B2 (en) | 2003-08-12 | 2011-01-27 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
JP5686494B2 (en) * | 2003-08-29 | 2015-03-18 | シオノギ インコーポレイテッド | Antibiotic preparations, their use and preparation |
EP1663169A4 (en) | 2003-09-15 | 2010-11-24 | Middlebrook Pharmaceuticals In | Antibiotic product, use and formulation thereof |
US20050112204A1 (en) * | 2003-11-25 | 2005-05-26 | Pfizer Inc. | Pharmaceutical formulations |
WO2005065648A2 (en) * | 2003-12-29 | 2005-07-21 | Alza Corporation, Inc., | Novel drug compositions and dosage forms of topiramate |
US20050175696A1 (en) * | 2003-12-29 | 2005-08-11 | David Edgren | Drug granule coatings that impart smear resistance during mechanical compression |
EP1701706A2 (en) * | 2003-12-29 | 2006-09-20 | Alza Corporation | Novel drug compositions and dosage forms |
JP2008505124A (en) | 2004-07-02 | 2008-02-21 | アドバンシス ファーマスーティカル コーポレイション | Pulse delivery tablets |
HUE028158T2 (en) | 2004-07-07 | 2016-12-28 | Biocon Ltd | Synthesis of azo bonded immunoregulatory compounds |
CA2630578C (en) * | 2005-11-30 | 2014-04-15 | Generex Pharmaceuticals Inc. | Orally absorbed pharmaceutical formulation and method of administration |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
AU2007204954A1 (en) * | 2006-01-10 | 2007-07-19 | Innovaform Technologies, Llc | Pesticide delivery system |
US8148338B2 (en) * | 2006-02-22 | 2012-04-03 | Supratek Pharma Inc. | Doxorubicin formulations for anti-cancer use |
US8299052B2 (en) * | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
KR20090009241A (en) * | 2006-05-18 | 2009-01-22 | 니폰 가야꾸 가부시끼가이샤 | Polymer conjugate of podophyllotoxin |
BRPI0603871B8 (en) * | 2006-08-24 | 2021-05-25 | Fundacao Univ De Brasilia | pharmaceutical compositions for the treatment of trypanosomiasis and chagas disease |
CA2717867C (en) | 2008-03-07 | 2017-05-30 | Paul J. Shami | Activated nitric oxide donors and methods of making and using thereof |
EP2265256A1 (en) * | 2008-03-17 | 2010-12-29 | University of Utah Research Foundation | Dithiocarbamate metal chelates and methods of making and using thereof |
US8445271B2 (en) | 2010-05-03 | 2013-05-21 | Enzo Life Sciences, Inc. | Processes and kits for determining multi-drug resistance of cells |
RU2501570C1 (en) * | 2012-05-11 | 2013-12-20 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Казанский (Приволжский) федеральный университет" (ФГАОУВПО КФУ) | Trifunctional ethylene oxide and propylene oxide block copolymers for active substance delivery to living cells |
US10792331B2 (en) * | 2015-09-09 | 2020-10-06 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Methods for reducing cardiotoxicity from chemotherapy by administering humanin analog compositions |
CN109324512A (en) * | 2018-12-05 | 2019-02-12 | 华北电力大学 | A method of depression of order automatic disturbance rejection controller parameter is adjusted using known models information |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5143731A (en) * | 1990-08-07 | 1992-09-01 | Mediventures Incorporated | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
DE69329792T2 (en) * | 1992-10-08 | 2001-05-31 | Supratek Pharma Inc | COMPOSITION OF ANTINEOPLASTIC ACTIVE SUBSTANCES INCLUDED IN MICELS |
-
1995
- 1995-06-07 US US08/478,978 patent/US5817321A/en not_active Expired - Lifetime
-
1996
- 1996-06-07 BR BR9609176A patent/BR9609176A/en not_active Application Discontinuation
- 1996-06-07 NZ NZ313271A patent/NZ313271A/en unknown
- 1996-06-07 AU AU65297/96A patent/AU700021B2/en not_active Ceased
- 1996-06-07 CA CA002222776A patent/CA2222776A1/en not_active Abandoned
- 1996-06-07 CN CN96196107A patent/CN1192678A/en active Pending
- 1996-06-07 EP EP96925056A patent/EP0871432B1/en not_active Expired - Lifetime
- 1996-06-07 JP JP50028697A patent/JP4167299B2/en not_active Expired - Fee Related
- 1996-06-07 WO PCT/IB1996/000799 patent/WO1996040055A2/en active IP Right Grant
- 1996-06-07 DE DE69630615T patent/DE69630615T2/en not_active Expired - Lifetime
- 1996-06-07 EP EP03075259A patent/EP1310244A3/en not_active Withdrawn
- 1996-06-07 AT AT96925056T patent/ATE253352T1/en not_active IP Right Cessation
- 1996-06-07 RU RU98100213/14A patent/RU2166934C2/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD4009C2 (en) * | 2008-07-15 | 2010-08-31 | Институт Химии Академии Наук Молдовы | Use of 1-methyl-4-(N-methylaminobutyl-4)-b-carboline as antituberculous remedy |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU98100213A (en) | COMPOSITIONS INCLUDING BIOLOGICAL AGENT | |
RU2166934C2 (en) | Compositions containing biological agent | |
Zhang et al. | Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel | |
US5541232A (en) | Treatment of multidrug resistant diseases | |
EP1282447B1 (en) | Stable polymeric micelle-type drug composition and method for the preparation thereof | |
EP1280557B1 (en) | Method for the preparation of polymeric micelle via phase separation of block copolymer | |
HUP9903952A2 (en) | Water soluble pharmaceutical compositions containing taxane derivatives | |
CA2125401A1 (en) | Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of making and using them | |
GB2144327A (en) | Composition for the embolization of blood vessels/radiopaques | |
EP1539109B1 (en) | Block copolymer micelle composition having an enhanced drug-loading capacity and sustained release | |
GEP20043375B (en) | APRIL-Receptor (BCMA) and Use Thereof | |
Cammas et al. | Functional poly [(ethylene oxide)‐co‐(β‐benzyl‐L‐aspartate)] polymeric micelles: block copolymer synthesis and micelles formation | |
RU2000123171A (en) | COMPOSITIONS CONTAINING EPOTHYLON | |
BR9916881A (en) | Methods for treating ovarian cancer, poly (phosphoester) compositions and biodegradable articles | |
GEP20043250B (en) | Use of Indolyl-3-Glyoxylic Acid Derivatives as Anti-tumor Means and Pharmaceutical Compositions Containing the Same | |
PL198185B1 (en) | Compositions and uses of et743 for treating cancer | |
CA2225807C (en) | Use of lamellarin-class alkaloids in methods of treatment | |
ME00056B (en) | A combination comprising combretastatin and anticancer agents | |
Itokazu et al. | Local drug delivery system using ceramics: vacuum method for impregnating a chemotherapeutic agent into a porous hydroxyapatite block | |
Chowdhary et al. | Formulation of Benzoporphyrin Derivatives in Pluronics¶ | |
CZ301378B6 (en) | Medicament intended for treating hepatocellular carcinoma | |
Rodriguez et al. | Blending of diblock and triblock copolypeptide amphiphiles yields cell penetrating vesicles with low toxicity | |
Bleday et al. | Inhibition of rat colon tumor isograft growth with dequalinium chloride | |
JP2002521456A (en) | How to use somatostatin analogs | |
Zhou et al. | Bio-inspired cisplatin nanocarriers for osteosarcoma treatment |